trifluridine has been researched along with Stomach Neoplasms in 35 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (8.57) | 29.6817 |
| 2010's | 6 (17.14) | 24.3611 |
| 2020's | 26 (74.29) | 2.80 |
| Authors | Studies |
|---|---|
| Alsina, M; Benhadji, KA; Cicin, I; Doi, T; Hosaka, H; Ilson, DH; Longo, F; Makris, L; Özgüroğlu, M; Ozyilkan, O; Park, D; Pericay, C; Santoro, A; Shitara, K; Thuss-Patience, P; Zaanan, A | 1 |
| Arkenau, HT; Fostea, RM | 1 |
| Arkenau, HT; Benhadji, KA; Doi, T; Falcone, A; George, B; Hochster, H; Ilson, DH; Makris, L; Mayer, R; Ohtsu, A; Shitara, K; Tabernero, J; Van Cutsem, E; Yoshino, T | 1 |
| Cheung, WY; Ding, PQ; Dolley, A | 1 |
| Aoyama, T; Furusawa, K; Furuta, M; Hamaguchi, T; Hashimoto, I; Hayashi, K; Inokuchi, Y; Kanematsu, K; Kano, K; Machida, N; Nagasawa, S; Ogata, T; Onuma, S; Oshima, T; Rino, Y; Suematsu, H; Watanabe, M; Yamada, T | 1 |
| Benhadji, KA; Doi, T; Ghidini, M; Hochster, H; Makris, L; Mansoor, W; Takahashi, O; Van Cutsem, E | 1 |
| Benhadji, KA; Fakih, MG; George, B; Ghidini, M; Makris, L; Shitara, K; Sundar, R; Taieb, J | 1 |
| Furusawa, K; Furuse, J; Furuta, M; Hamaguchi, T; Hashimoto, I; Hayashi, K; Inokuchi, Y; Kanematsu, K; Machida, N; Maeda, S; Nagasawa, S; Notsu, A; Ogata, T; Onuma, S; Oshima, T; Suematsu, H; Watanabe, M; Yamada, T | 1 |
| Chen, ZM; Han, WX; Luo, PQ; Wang, G; Wei, ZJ; Xu, AM; Ying, S; Zhang, LX; Zhu, H | 1 |
| Al-Batran, SE; Brulin, T; Goekkurt, E; Goetze, TO; Habibzada, T; Herhaus, P; Ihrig, K; Loose, M; Lorenzen, S; Pauligk, C; Sookthai, D; Stein, A | 1 |
| Boku, N; Hara, H; Hirata, K; Hironaka, S; Kawakami, H; Masuishi, T; Matsumoto, T; Muro, K; Nagashima, K; Takahashi, N; Yamazaki, K | 1 |
| Kawazoe, A; Kotani, D; Kuboki, Y; Mishima, S; Nakamura, H; Nakamura, Y; Okunaka, M; Shitara, K | 1 |
| Alsina, M; Arkenau, HT; Beretta, GD; Catenacci, D; Doi, T; Fujitani, K; George, B; Ghidini, M; Ilson, DH; Makris, L; Mansoor, W; McGuigan, S; Prokharau, A; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Zhavrid, E | 1 |
| Alsina, M; Amellal, N; Ando, T; Arkenau, HT; Doi, T; Dvorkin, M; Faustino, C; Ghidini, M; Gorbunova, V; Ilson, DH; Leger, C; Mansoor, W; Nishikawa, K; Prokharau, A; Sabater, J; Shitara, K; Skanji, D; Tabernero, J; Van Cutsem, E; Yalçın, Ş; Zhavrid, E | 1 |
| Aprile, G; Cianchi, F; Fancelli, S; Gatta Michelet, MR; Lavacchi, D; Mini, E; Nobili, S; Roviello, F; Roviello, G | 1 |
| Bonetti, A; Giuliani, J | 1 |
| Kawai, S; Kawakami, H; Misumi, T; Mizukami, T; Moriwaki, T; Muro, K; Nakamura, M; Narita, Y; Nishina, T; Shoji, H; Sunakawa, Y; Yamanaka, T | 1 |
| He, X; Wu, L; Wu, Y; Zhang, T; Zhou, X | 1 |
| Hamada, S; Ikeda, J; Komatsu, S; Konishi, T; Matsubara, D; Shibata, R; Shimomura, K; Shioaki, Y; Soga, K; Taniguchi, F | 1 |
| Amagai, K; Ando, T; Fujita, J; Fujitani, K; Hosaka, H; Kawazoe, A; Koeda, K; Nishikawa, K; Ogata, K; Shitara, K; Watanabe, K; Yamamoto, Y | 1 |
| Sonbol, MB; Yoon, HH; Zhu, M | 1 |
| Alsina, M; Ando, T; Arkenau, HT; Benhadji, KA; Beretta, GD; Cuffe, S; Doi, T; Dvorkin, M; Ilson, DH; Makris, L; Mansoor, W; Park, D; Shitara, K; Tabernero, J; Thuss-Patience, P; Van Cutsem, E; Van Den Eynde, M; Zaniboni, A | 1 |
| Androulakis, N; Beletsi, A; Boukovinas, I; Chotzagiannoglou, V; Gourzoulidis, G; Karamouzis, M; Koulentaki, M; Koumarianou, A; Kourlaba, G; Papakotoulas, P; Samadas, E; Souglakos, J; Xynogalos, S | 1 |
| Doi, T; Igarashi, A; Shitara, K; Takushima, Y; Yoshihara, H | 1 |
| Alsina, M; Arkenau, HT; Azcue, P; Catenacci, DVT; Doi, T; Fornaro, L; Fougeray, R; Ilson, DH; Lorenzen, S; Moreno, SR; Shitara, K; Tabernero, J; Van Cutsem, E; Zaanan, A | 1 |
| Nienhüser, H; Schmidt, T | 1 |
| Alsina, M; Arkenau, HT; Beretta, GD; Cutsem, EV; Doi, T; Dvorkin, M; Faustino, C; Fujitani, K; Ghidini, M; Gorbunova, V; Hosokawa, A; Ilson, DH; Makris, L; Mansoor, W; Nishikawa, K; Prokharau, A; Shitara, K; Tabernero, J; Winkler, RE; Yalçın, Ş; Zhavrid, E | 1 |
| Fu, H; Kim, DH; McCaw, ZR; Tian, L; Wei, LJ | 1 |
| Li, Q; Liao, W; Zhang, M; Zhou, J; Zhou, K | 1 |
| Nakagawa, F; Nukatsuka, M; Saito, H; Sakata, M; Takechi, T; Uchida, J | 1 |
| Nakagawa, F; Nukatsuka, M; Takechi, T | 1 |
| Bando, H; Doi, T; Kuno, H; Muro, K; Nishina, T; Nomura, S; Ohtsu, A; Sato, A; Shitara, K; Takahashi, S; Yamaguchi, K; Yasui, H | 1 |
| Emura, T; Fujioka, A; Kitazato, K; Nakagawa, F; Ohshimo, H | 1 |
| Emura, T; Fujioka, A; Kitazato, K; Nakagawa, F; Ohshimo, H; Okabe, H; Yokogawa, T | 1 |
| Emura, T; Fukushima, M; Ohshimo, H; Suzuki, N; Yamaguchi, M | 1 |
2 review(s) available for trifluridine and Stomach Neoplasms
| Article | Year |
|---|---|
Trifluridine/tipiracil in the treatment of gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase III as Topic; Drug Combinations; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2022 |
TAS-102 in gastric cancer: Development and perspectives of a new biochemically modulated fluroropyrimidine drug combination.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biochemical Phenomena; Drug Combinations; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2020 |
12 trial(s) available for trifluridine and Stomach Neoplasms
| Article | Year |
|---|---|
Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS).
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophageal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2022 |
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancer.
Topics: Adult; Colonic Neoplasms; Colorectal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Neutropenia; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2022 |
Body weight loss as a prognostic and predictive factor in previously treated patients with metastatic gastric cancer: post hoc analyses of the randomized phase III TAGS trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Prognosis; Retrospective Studies; Stomach Neoplasms; Trifluridine; Uracil; Weight Loss | 2023 |
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophagogastric Junction; Humans; Irinotecan; Paclitaxel; Pyrrolidines; Stomach Neoplasms; Trifluridine | 2023 |
Randomised phase II trial of trifluridine/tipiracil (FTD/TPI) plus ramucirumab (RAM) versus trifluridine/tipiracil for previously treated patients with advanced gastric or esophagogastric junction adenocarcinoma (RETRIEVE study, WJOG15822G).
Topics: Adenocarcinoma; Adult; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Esophagogastric Junction; Frontotemporal Dementia; Humans; Prospective Studies; Ramucirumab; Stomach Neoplasms; Trifluridine; Young Adult | 2023 |
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Gastrectomy; Humans; Male; Middle Aged; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2020 |
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGS.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Double-Blind Method; Female; Follow-Up Studies; Humans; International Agencies; Male; Middle Aged; Prognosis; Pyrrolidines; Quality of Life; Stomach Neoplasms; Survival Rate; Thymine; Trifluridine; Young Adult | 2020 |
REVIVE study: a prospective observational study in chemotherapy after nivolumab therapy for advanced gastric cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Drug Resistance, Neoplasm; Humans; Irinotecan; Japan; Multicenter Studies as Topic; Neoplasm Staging; Nivolumab; Observational Studies as Topic; Oxaliplatin; Progression-Free Survival; Prospective Studies; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2021 |
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.
Topics: Adenocarcinoma; Administration, Intravenous; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Case-Control Studies; Drug Combinations; Esophageal Neoplasms; Female; Humans; Japan; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Pyrrolidines; Ramucirumab; Safety; Stomach Neoplasms; Thymine; Trifluridine | 2021 |
Trifluridine/tipiracil in patients with metastatic gastroesophageal junction cancer: a subgroup analysis from the phase 3 TAGS study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Drug Combinations; Esophagogastric Junction; Female; Humans; Male; Middle Aged; Neoplasm Metastasis; Proportional Hazards Models; Pyrrolidines; Stomach Neoplasms; Survival Rate; Thymine; Treatment Outcome; Trifluridine; Young Adult | 2021 |
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Disease Progression; Double-Blind Method; Drug Combinations; Europe; Female; Humans; Israel; Japan; Male; Middle Aged; Neoplasm Staging; Progression-Free Survival; Pyrrolidines; Stomach Neoplasms; Thymine; Time Factors; Trifluridine; United States; Uracil | 2018 |
A multicenter phase II study of TAS-102 monotherapy in patients with pre-treated advanced gastric cancer (EPOC1201).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Drug Combinations; Female; Humans; Male; Middle Aged; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2016 |
21 other study(ies) available for trifluridine and Stomach Neoplasms
| Article | Year |
|---|---|
Trifluridine/Tipiracil in the Real-World Management of Metastatic Gastric and Gastroesophageal Junction Cancers in Canada.
Topics: Adult; Aged; Canada; Colorectal Neoplasms; Esophageal Neoplasms; Esophagogastric Junction; Frontotemporal Dementia; Humans; Stomach Neoplasms; Trifluridine; Uracil | 2022 |
Clinical Significance of Neutrophil-to-Lymphocyte Ratio/Serum Albumin Ratio in Patients With Metastatic Gastric or Gastroesophageal Junction Cancer Administered Trifluridine/Tipiracil.
Topics: Clinical Relevance; Esophagogastric Junction; Frontotemporal Dementia; Humans; Lymphocytes; Neutrophils; Prognosis; Retrospective Studies; Serum Albumin; Stomach Neoplasms; Trifluridine | 2023 |
Evaluation of Irinotecan and Trifluridine/Tipiracil as Fourth-line Treatments After Third-line Nivolumab for Advanced Gastric Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Frontotemporal Dementia; Humans; Irinotecan; Nivolumab; Stomach Neoplasms; Trifluridine; Uracil | 2023 |
Effects and mechanisms of trifluridine alone or in combination with cryptotanshinone in inhibiting malignant biological behavior of gastric cancer.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Synergism; Heterografts; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Phenanthrenes; STAT3 Transcription Factor; Stomach Neoplasms; Trifluridine | 2023 |
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy.
Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Esophagogastric Junction; Humans; Ramucirumab; Stomach Neoplasms; Treatment Failure; Trifluridine | 2023 |
Efficacy and safety of trifluridine/tipiracil plus ramucirumab in comparison with trifluridine/tipiracil monotherapy for patients with advanced gastric cancer-single institutional experience.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Ramucirumab; Retrospective Studies; Stomach Neoplasms; Trifluridine; Uracil | 2023 |
Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.
Topics: Drug Combinations; Drug Costs; Humans; Neoplasm Metastasis; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2020 |
The effect of trifluridine/tipiracil for patients with heavily pretreated metastatic gastric cancer: A protocol for systematic review and meta-analysis.
Topics: Adolescent; Adult; Aged; Clinical Protocols; Drug Combinations; Humans; Meta-Analysis as Topic; Middle Aged; Pyrrolidines; Stomach Neoplasms; Systematic Reviews as Topic; Thymine; Trifluridine | 2021 |
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Drug Combinations; Humans; Neoplasm Recurrence, Local; Pyrrolidines; Stomach Neoplasms; Survivors; Thymine; Trifluridine; Uracil | 2020 |
Trifluridine/tipiracil plus ramucirumab in gastric cancer.
Topics: Antibodies, Monoclonal, Humanized; Humans; Pyrrolidines; Ramucirumab; Stomach Neoplasms; Thymine; Trifluridine | 2021 |
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Greece.
Topics: Adenocarcinoma; Colorectal Neoplasms; Cost-Benefit Analysis; Greece; Humans; Pyrrolidines; Quality-Adjusted Life Years; Stomach Neoplasms; Thymine; Trifluridine | 2022 |
Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Topics: Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Cost-Benefit Analysis; Drug Combinations; Humans; Japan; Nivolumab; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2021 |
Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
Topics: Colorectal Neoplasms; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2021 |
9 weeks that matter for patients with gastric cancer.
Topics: Double-Blind Method; Gastrectomy; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2018 |
Trifluridine/tipiracil in metastatic gastric cancer.
Topics: Double-Blind Method; Drug Combinations; Humans; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine | 2019 |
Cost-effectiveness of trifluridine/tipiracil (TAS102) for heavily pretreated metastatic gastric cancer.
Topics: Clinical Trials as Topic; Cost-Benefit Analysis; Drug Combinations; Drug Costs; Humans; Markov Chains; Progression-Free Survival; Pyrrolidines; Quality-Adjusted Life Years; Stomach Neoplasms; Thymine; Trifluridine; Uracil | 2020 |
Efficacy of combination chemotherapy using a novel oral chemotherapeutic agent, TAS-102, with irinotecan hydrochloride on human colorectal and gastric cancer xenografts.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cell Line, Tumor; Colorectal Neoplasms; Drug Combinations; Fluorouracil; Humans; Irinotecan; Male; Mice; Pyrrolidines; Stomach Neoplasms; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays | 2015 |
Efficacy of Combination Chemotherapy Using a Novel Oral Chemotherapeutic Agent, TAS-102, with Oxaliplatin on Human Colorectal and Gastric Cancer Xenografts.
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Body Weight; Cell Death; Cell Proliferation; Colorectal Neoplasms; Drug Combinations; HCT116 Cells; Humans; Mice, Nude; Organoplatinum Compounds; Oxaliplatin; Pyrrolidines; Stomach Neoplasms; Thymine; Treatment Outcome; Trifluridine; Tumor Burden; Uracil; Xenograft Model Antitumor Assays | 2015 |
Thymidine kinase and thymidine phosphorylase level as the main predictive parameter for sensitivity to TAS-102 in a mouse model.
Topics: Animals; Antineoplastic Agents; Cell Division; Drug Combinations; Head and Neck Neoplasms; Humans; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Pancreatic Neoplasms; Pyrrolidines; Stomach Neoplasms; Thymidine Kinase; Thymidine Phosphorylase; Thymidylate Synthase; Thymine; Transplantation, Heterologous; Trifluridine; Uracil | 2004 |
An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA.
Topics: Animals; Antimetabolites, Antineoplastic; DNA; Dose-Response Relationship, Drug; Humans; In Vitro Techniques; Mice; Pancreatic Neoplasms; Stomach Neoplasms; Thymidine Phosphorylase; Time Factors; Transplantation, Heterologous; Trifluridine | 2004 |
A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Topics: Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Colonic Neoplasms; DNA Damage; DNA, Neoplasm; Drug Combinations; Drug Resistance, Neoplasm; Floxuridine; Fluorouracil; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Pyrrolidines; Rats; Rats, Nude; Stomach Neoplasms; Thymine; Trifluridine; Uracil; Xenograft Model Antitumor Assays | 2004 |